Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%

NCT07689149 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplantation Recipients
HLA Sensitization

Interventions

DRUG: BiTE (CD19 x CD3 Bispecific Antibody)
DRUG: BiTE (BCMA x CD3 Bispecific Antibody)

Sponsor

West China Hospital